ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 262 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $99,802,719 | -20.8% | 4,788,998 | -9.0% | 0.10% | -19.4% |
| Q2 2023 | $126,050,718 | +36.7% | 5,263,078 | +7.4% | 0.13% | +30.3% |
| Q1 2023 | $92,228,953 | +37.3% | 4,900,582 | +16.1% | 0.10% | +33.8% |
| Q4 2022 | $67,172,832 | -12.9% | 4,219,399 | -10.5% | 0.07% | -19.6% |
| Q3 2022 | $77,092,000 | +16.7% | 4,712,180 | +0.5% | 0.09% | +19.5% |
| Q2 2022 | $66,035,000 | -40.0% | 4,686,665 | +3.1% | 0.08% | -25.2% |
| Q1 2022 | $110,128,000 | +4.2% | 4,546,963 | +0.4% | 0.10% | +17.0% |
| Q4 2021 | $105,665,000 | +14.2% | 4,527,203 | -18.7% | 0.09% | +6.0% |
| Q3 2021 | $92,527,000 | -20.4% | 5,570,532 | +16.9% | 0.08% | -17.0% |
| Q2 2021 | $116,220,000 | +91.3% | 4,765,065 | +102.3% | 0.10% | +69.5% |
| Q1 2021 | $60,764,000 | -49.3% | 2,355,208 | +5.0% | 0.06% | -44.9% |
| Q4 2020 | $119,900,000 | +28.4% | 2,242,800 | -1.0% | 0.11% | +11.5% |
| Q3 2020 | $93,411,000 | -10.3% | 2,264,513 | +5.4% | 0.10% | -22.6% |
| Q2 2020 | $104,124,000 | +91.0% | 2,148,208 | +66.5% | 0.12% | +45.9% |
| Q1 2020 | $54,508,000 | -7.5% | 1,290,129 | -6.3% | 0.08% | +26.9% |
| Q4 2019 | $58,912,000 | -28.0% | 1,377,094 | -39.4% | 0.07% | -33.7% |
| Q3 2019 | $81,783,000 | +60.9% | 2,272,384 | +19.5% | 0.10% | +60.3% |
| Q2 2019 | $50,836,000 | +31.5% | 1,901,850 | +32.1% | 0.06% | +26.0% |
| Q1 2019 | $38,663,000 | +1501.0% | 1,439,981 | +864.2% | 0.05% | +1566.7% |
| Q4 2018 | $2,415,000 | +181.1% | 149,342 | +165.4% | 0.00% | +200.0% |
| Q2 2018 | $859,000 | -39.3% | 56,267 | +19.7% | 0.00% | -50.0% |
| Q4 2017 | $1,415,000 | -42.6% | 47,000 | -28.2% | 0.00% | -50.0% |
| Q3 2017 | $2,464,000 | +87.9% | 65,429 | +39.2% | 0.00% | +100.0% |
| Q2 2017 | $1,311,000 | -56.4% | 47,000 | -46.3% | 0.00% | -60.0% |
| Q1 2017 | $3,007,000 | -45.9% | 87,458 | -54.6% | 0.01% | -50.0% |
| Q4 2016 | $5,554,000 | -19.1% | 192,546 | -10.8% | 0.01% | -16.7% |
| Q3 2016 | $6,867,000 | +171.9% | 215,883 | +177.4% | 0.01% | +200.0% |
| Q2 2016 | $2,526,000 | +2.0% | 77,820 | -12.1% | 0.00% | 0.0% |
| Q1 2016 | $2,476,000 | +7.3% | 88,566 | +36.8% | 0.00% | +33.3% |
| Q4 2015 | $2,308,000 | +49.2% | 64,750 | +38.4% | 0.00% | +50.0% |
| Q3 2015 | $1,547,000 | -18.5% | 46,776 | +3.2% | 0.00% | -33.3% |
| Q2 2015 | $1,898,000 | +97.7% | 45,331 | +53.9% | 0.00% | +200.0% |
| Q1 2015 | $960,000 | -91.4% | 29,449 | -91.6% | 0.00% | -92.9% |
| Q4 2014 | $11,180,000 | +44.0% | 352,101 | +12.3% | 0.01% | +55.6% |
| Q3 2014 | $7,762,000 | +10.4% | 313,539 | +0.7% | 0.01% | -10.0% |
| Q2 2014 | $7,033,000 | +9.3% | 311,315 | +17.8% | 0.01% | +11.1% |
| Q1 2014 | $6,432,000 | -31.7% | 264,364 | -29.8% | 0.01% | -25.0% |
| Q4 2013 | $9,411,000 | -1.9% | 376,617 | +7.8% | 0.01% | -25.0% |
| Q3 2013 | $9,595,000 | +58.9% | 349,304 | +5.0% | 0.02% | +45.5% |
| Q2 2013 | $6,037,000 | – | 332,642 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |